IL237872B - Purification of immunoglobulin hetero-dimers - Google Patents

Purification of immunoglobulin hetero-dimers

Info

Publication number
IL237872B
IL237872B IL237872A IL23787215A IL237872B IL 237872 B IL237872 B IL 237872B IL 237872 A IL237872 A IL 237872A IL 23787215 A IL23787215 A IL 23787215A IL 237872 B IL237872 B IL 237872B
Authority
IL
Israel
Prior art keywords
hetero
purification
dimeric immunoglobulins
dimeric
immunoglobulins
Prior art date
Application number
IL237872A
Other languages
English (en)
Hebrew (he)
Other versions
IL237872A0 (en
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of IL237872A0 publication Critical patent/IL237872A0/en
Publication of IL237872B publication Critical patent/IL237872B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL237872A 2012-09-25 2015-03-22 Purification of immunoglobulin hetero-dimers IL237872B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261705278P 2012-09-25 2012-09-25
PCT/EP2013/069989 WO2014049003A1 (en) 2012-09-25 2013-09-25 Purification of hetero-dimeric immunoglobulins

Publications (2)

Publication Number Publication Date
IL237872A0 IL237872A0 (en) 2015-05-31
IL237872B true IL237872B (en) 2019-09-26

Family

ID=49237223

Family Applications (2)

Application Number Title Priority Date Filing Date
IL237872A IL237872B (en) 2012-09-25 2015-03-22 Purification of immunoglobulin hetero-dimers
IL269207A IL269207B (en) 2012-09-25 2019-09-09 Purification of immunoglobulin hetero-dimers

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL269207A IL269207B (en) 2012-09-25 2019-09-09 Purification of immunoglobulin hetero-dimers

Country Status (11)

Country Link
US (2) US20150239991A1 (enExample)
EP (2) EP2900696A1 (enExample)
JP (5) JP2015529236A (enExample)
KR (1) KR20150076172A (enExample)
CN (1) CN104968685A (enExample)
AU (2) AU2013322710A1 (enExample)
CA (2) CA2886036A1 (enExample)
HK (1) HK1215950A1 (enExample)
IL (2) IL237872B (enExample)
IN (1) IN2015MN00139A (enExample)
WO (1) WO2014049003A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
WO2010115589A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Trivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US20120302737A1 (en) 2009-09-16 2012-11-29 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
BR112013001847A2 (pt) 2010-08-24 2016-05-31 Hoffmann La Roche anticorpo biespecífico, método de preparação do anticorpo biespecífico, do anticorpo biespecífico trivalente, métodos e composição farmacêutica
JP5764677B2 (ja) 2011-02-28 2015-08-19 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗原結合タンパク質
CA2824824A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
WO2014049003A1 (en) * 2012-09-25 2014-04-03 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
CN105143262A (zh) 2013-04-29 2015-12-09 豪夫迈·罗氏有限公司 结合人fcrn的修饰的抗体和使用方法
WO2015033223A2 (en) * 2013-09-03 2015-03-12 Novimmune S.A. Readily isolated bispecific binding molecules with native format having mutated constant regions
RU2016115866A (ru) 2013-10-11 2017-11-16 Ф. Хоффманн-Ля Рош Аг Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
PE20160724A1 (es) 2013-11-04 2016-08-04 Glenmark Pharmaceuticals Sa Produccion de inmunoglobulinas heterodimericas de redireccionamiento de celulas t
WO2015107015A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with improved protein a-binding
AU2015237184B2 (en) 2014-03-28 2020-11-26 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
AR101262A1 (es) * 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
EP3174897B1 (en) * 2014-07-29 2020-02-12 F.Hoffmann-La Roche Ag Multispecific antibodies
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
PE20171103A1 (es) 2014-11-26 2017-08-07 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y cd38
JP6721590B2 (ja) 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
EP3319996B1 (en) 2015-07-09 2024-01-03 Genmab A/S Bispecific and multispecific antibodies and method for isolation of such
EP3365366B1 (en) 2015-10-25 2021-07-14 Sanofi Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
GB201602156D0 (en) * 2016-02-05 2016-03-23 Jones Philip C And Boku University Of Natural Resources And Life Sciences Heterodimers and purification thereof
FI3443006T3 (fi) 2016-04-13 2023-10-23 Sanofi Sa Trispesifisiä ja/tai kolmiarvoisia sitojaproteiineja
EP3452502B1 (en) * 2016-05-02 2021-03-03 H. Hoffnabb-La Roche Ag The contorsbody - a single chain target binder
IL265605B2 (en) * 2016-09-29 2024-06-01 Beijing Hanmi Pharmaceutical Co Ltd Heterodimeric immunoglobulin constructs, pharmaceutical composition comprising the same, use and preparation methods thereof
WO2018090950A1 (zh) 2016-11-18 2018-05-24 北京韩美药品有限公司 抗pd‐1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
MA44670B1 (fr) * 2017-03-17 2023-11-30 Sanofi Sa Protéines de liaison trispécifiques et/ou trivalentes
KR102732040B1 (ko) 2017-04-11 2024-11-21 인히브릭스 바이오사이언스, 인크. 제한된 ｃｄ3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 이를 이용한 방법
WO2019153200A1 (zh) 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
CN111902720B (zh) 2018-03-21 2025-02-07 沃特世科技公司 基于非抗体高亲和力的样品制备、吸附剂、装置和方法
WO2019200022A1 (en) 2018-04-11 2019-10-17 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
FR3080621B1 (fr) * 2018-04-26 2022-12-09 Univ Limoges Nouvelle classe d'immunoglobuline recombinante de type g : igg5, codee par le pseudo-gene gamma humain de chaine lourde
EP3810649A1 (en) 2018-06-22 2021-04-28 Genmab A/S Method for producing a controlled mixture of two or more different antibodies
US12195533B2 (en) 2018-07-24 2025-01-14 Inhibrx Biosciences, Inc. Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the same
US20210340273A1 (en) 2018-10-11 2021-11-04 Inhlbrx, inc. 5t4 single domain antibodies and therapeutic compositions thereof
US11208485B2 (en) 2018-10-11 2021-12-28 Inhibrx, Inc. PD-1 single domain antibodies and therapeutic compositions thereof
US20230124851A1 (en) 2018-10-11 2023-04-20 Inhibrx, lnc. B7h3 single domain antibodies and therapeutic compositions thereof
WO2020076977A2 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
WO2020136564A1 (en) 2018-12-24 2020-07-02 Sanofi Pseudofab-based multispecific binding proteins
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
IL293845A (en) * 2019-12-26 2022-08-01 Abl Bio Inc Method for purifying biologically active peptide by using protein a affinity chromatography
IL294879A (en) 2020-01-29 2022-09-01 Inhibrx Inc Cd28 single domain antibodies and multivalent and multispecific constructs thereof
WO2022077006A1 (en) 2020-10-07 2022-04-14 Dren Bio, Inc. Anti-dectin-1 antibodies and methods of use thereof
JP2024527262A (ja) 2021-06-16 2024-07-24 アレクトル エルエルシー 二重特異性抗ＭｅｒＴＫ及び抗ＰＤＬ１抗体ならびにその使用方法
WO2022266221A1 (en) 2021-06-16 2022-12-22 Alector Llc Monovalent anti-mertk antibodies and methods of use thereof
JP2023092810A (ja) * 2021-12-22 2023-07-04 国立大学法人東京農工大学 変異抗体、変異抗体の製造方法
CN119584978A (zh) 2022-06-07 2025-03-07 再生元制药公司 用于调节t细胞活性的多特异性分子及其用途
JP2025528752A (ja) 2022-07-29 2025-09-02 アレクトル エルエルシー トランスフェリン受容体抗原結合ドメイン及びその使用法
CA3261511A1 (en) 2022-07-29 2024-02-01 Alector Llc CD98HC ANTIGEN BINDING DOMAINS AND THEIR USES
AU2023334360A1 (en) * 2022-09-02 2025-03-06 Zoetis Services Llc Equine antibody mutants
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
US12195546B2 (en) 2022-12-19 2025-01-14 Sanofi CD28/OX40 bispecific antibodies
WO2025038668A1 (en) 2023-08-14 2025-02-20 Voro Therapeutics, Inc. Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof
WO2025087386A1 (zh) * 2023-10-25 2025-05-01 正大天晴药业集团南京顺欣制药有限公司 抗her2抗体药物偶联物治疗乳腺癌的用途
WO2025166042A1 (en) 2024-01-31 2025-08-07 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2025166045A1 (en) 2024-01-31 2025-08-07 Alector Llc β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF
WO2025166077A1 (en) 2024-01-31 2025-08-07 Alector Llc Compositions comprising progranulin and uses thereof
WO2025166040A1 (en) 2024-01-31 2025-08-07 Alector Llc Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof
WO2025240670A2 (en) 2024-05-15 2025-11-20 Abalytics Oncology, Inc. Anti-pd-1 antibodies and related binding molecules and methods and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
DK0479909T3 (da) 1989-06-29 1997-04-07 Medarex Inc Bispecifikke reagenser til AIDS-behandling
JPH06500011A (ja) 1990-06-29 1994-01-06 ラージ　スケール　バイオロジー　コーポレイション 形質転換された微生物によるメラニンの製造
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE4419399C1 (de) 1994-06-03 1995-03-09 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0826696B1 (de) 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
US8142780B2 (en) * 1998-08-20 2012-03-27 Strox Biopharmaceuticals, Llc Anti-bacterial antibodies
US6322788B1 (en) * 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
ES2402650T3 (es) * 2005-06-17 2013-05-07 Janssen Alzheimer Immunotherapy Métodos de purificación de anticuerpos anti A beta
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
US8871912B2 (en) 2006-03-24 2014-10-28 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
SI2129396T1 (sl) 2007-02-16 2013-12-31 Merrimack Pharmaceuticals, Inc. Protitelesa proti ErbB3 in njihove uporabe
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
WO2010037836A2 (en) * 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific psmaxcd3 bispecific single chain antibody
US20120009182A1 (en) * 2008-12-23 2012-01-12 Genentech, Inc. Immunoglobulin variants with altered binding to protein a
US8679492B2 (en) 2009-02-23 2014-03-25 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to CD19 and their uses
AR075896A1 (es) 2009-03-20 2011-05-04 Genentech Inc Anticuerpos anti-her (factor de crecimiento epidermico)
RU2522002C2 (ru) 2009-06-26 2014-07-10 Ридженерон Фармасьютикалз, Инк. Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом
WO2011078332A1 (ja) * 2009-12-25 2011-06-30 中外製薬株式会社 ポリペプチド多量体を精製するためのポリペプチドの改変方法
EA201201435A1 (ru) * 2010-04-20 2013-04-30 Генмаб А/С ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
NZ608724A (en) 2011-03-25 2015-12-24 Glenmark Pharmaceuticals Sa Hetero-dimeric immunoglobulins
US9114516B2 (en) 2011-07-21 2015-08-25 Illinois Tool Works Inc. Portable combustion gas-powered tools with combustion chamber lockout system
LT2771364T (lt) * 2011-10-27 2019-09-10 Genmab A/S Heterodimerinių baltymų gamyba
US20150088787A1 (en) 2012-03-06 2015-03-26 Foss Analytical Ab Method, software and graphical user interface for forming a prediction model for chemometric analysis
EP3517548A1 (en) 2012-03-13 2019-07-31 NovImmune S.A. Readily isolated bispecific antibodies with native immunoglobulin format
WO2014049003A1 (en) * 2012-09-25 2014-04-03 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
PE20160724A1 (es) * 2013-11-04 2016-08-04 Glenmark Pharmaceuticals Sa Produccion de inmunoglobulinas heterodimericas de redireccionamiento de celulas t

Also Published As

Publication number Publication date
JP6856610B2 (ja) 2021-04-07
JP2018104444A (ja) 2018-07-05
JP2015529236A (ja) 2015-10-05
EP2900696A1 (en) 2015-08-05
KR20150076172A (ko) 2015-07-06
CN104968685A (zh) 2015-10-07
US20150239991A1 (en) 2015-08-27
WO2014049003A1 (en) 2014-04-03
AU2013322710A1 (en) 2015-04-16
EP3401337A1 (en) 2018-11-14
AU2013322710A2 (en) 2015-05-07
AU2018204314A1 (en) 2018-07-05
JP2019073512A (ja) 2019-05-16
CA2886036A1 (en) 2014-04-03
HK1215950A1 (zh) 2016-09-30
JP2020105203A (ja) 2020-07-09
JP2022116326A (ja) 2022-08-09
US20200010568A1 (en) 2020-01-09
IL269207A (en) 2019-11-28
AU2018204314B2 (en) 2020-05-14
IL237872A0 (en) 2015-05-31
IN2015MN00139A (enExample) 2015-10-16
IL269207B (en) 2022-02-01
CA3061557A1 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
IL269207B (en) Purification of immunoglobulin hetero-dimers
IL270815A (en) Immunoglobulins hetero-dimers
IL287057A (en) Purified iduronate-2-sulfatase
ZA201507087B (en) Selective separation of nitroso-containing compounds
SG11201502555QA (en) Purification system
ZA201403108B (en) Purification of anti-c-met antibodies
SG11201603028SA (en) Purification of proteins
EP2867792A4 (en) ACHIEVING PREDICTED ACTIONS
SG11201403891SA (en) Purification of flaviviruses
HRP20190030T1 (hr) Postupak pročišćavanja protutijela
EP2800747A4 (en) POLYMORPHY OF PERAMPANEL
SG11201406111YA (en) Purification of succinic acid
SG11201406800UA (en) Purification of air
EP2723759A4 (en) PURIFICATION OF CHIMERIC PROTEIN
LT3202769T (lt) Fosfaplatinos junginių gryninimo būdas
GB201209082D0 (en) Purification method
GB201202393D0 (en) Polymorphs
DK2838850T3 (da) Oprensning af titantetrachlorid
EP2714713A4 (en) PURIFICATION OF ANTIBODIES
PL2733011T3 (pl) Osprzęt sieci trakcyjnej
IL233446A0 (en) Polymorphic forms of paramphenel
GB201203494D0 (en) Hydrophobin purification
EP2814499A4 (en) PURIFICATION PROCESS
GB201105866D0 (en) This is about me
TWM433525U (en) Structure of calorifier

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed